Waverly Capital

Camera IQ Inc. is a company based in Santa Monica, California, that specializes in creating a camera experience management platform designed for digital marketers. Founded in 2013, the company offers a suite of tools that integrate operating system platforms, augmented reality toolkits, and native applications, facilitating the creation, deployment, and measurement of augmented reality content. Camera IQ's technology allows brands to design and implement scalable marketing and advertising experiences specifically for smartphone cameras, enabling them to engage audiences effectively across social media and streaming platforms. By combining experience design with spatial analytics, Camera IQ helps clients craft immersive environments that resonate with customers.

Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.